PDF(Pubmed)
Abstract：
The outbreak of monkeypox, coupled with the onslaught of the COVID-19 pandemic is a critical communicable disease. This study aimed to systematically identify and review research done on preclinical studies focusing on the potential monkeypox treatment and immunization. The presented juxtaposition of efficacy of potential treatments and vaccination that had been tested in preclinical trials could serve as a useful primer of monkeypox virus. The literature identified using key terms such as monkeypox virus or management or vaccine stringed using Boolean operators was systematically reviewed. Pubmed, SCOPUS, Cochrane, and preprint databases were used, and screening was performed in accordance with PRISMA guidelines. A total of 467 results from registered databases and 116 from grey literature databases were screened. Of these results, 72 studies from registered databases and three grey literature studies underwent full-text screening for eligibility. In this systematic review, a total of 27 articles were eligible according to the inclusion criteria and were used. Tecovirimat, known as TPOXX or ST-246, is an antiviral drug indicated for smallpox infection whereas brincidofovir inhibits the viral DNA polymerase after incorporation into viral DNA. The ability of tecovirimat in providing protection to poxvirus-challenged animals from death had been demonstrated in a number of animal studies. Non-inferior with regard to immunogenicity was reported for the live smallpox/monkeypox vaccine compared with a single dose of a licensed live smallpox vaccine. The trial involving the live vaccine showed a geometric mean titre of vaccinia-neutralizing antibodies post two weeks of the second dose of the live smallpox/monkeypox vaccine. Of note, up to the third generation of smallpox vaccines-particularly JYNNEOS and Lc16m8-have been developed as preventive measures for MPXV infection and these vaccines had been demonstrated to have improved safety compared to the earlier generations.
摘要：
猴痘的爆发,再加上COVID-19大流行的袭击，是一种严重的传染病。本研究旨在系统地识别和回顾临床前研究的研究，重点是潜在的猴痘治疗和免疫接种。已在临床前试验中测试的潜在治疗和疫苗接种的功效并置可以作为猴痘病毒的有用引物。系统回顾了使用关键术语（例如猴痘病毒或使用布尔运算符串接的管理或疫苗）鉴定的文献。Pubmed,Scopus,科克伦,使用预打印数据库，并按照PRISMA指南进行筛查.共筛选了注册数据库的467个结果和灰色文献数据库的116个结果。在这些结果中,来自注册数据库的72项研究和3项灰色文献研究进行了全文筛选。在这次系统审查中，根据纳入标准，共有27篇文章符合条件，并被使用。Tecovirimat,称为TPOXX或ST-246，是一种用于天花感染的抗病毒药物，而布列多福韦在掺入病毒DNA后抑制病毒DNA聚合酶。在许多动物研究中已经证明了tecovirimat为痘病毒攻击的动物提供保护免受死亡的能力。据报道，与单剂量的许可的天花活疫苗相比，天花/猴痘活疫苗的免疫原性不差。涉及活疫苗的试验显示，在第二剂天花/猴痘活疫苗的两周后，牛痘中和抗体的几何平均滴度。值得注意的是，直到第三代天花疫苗-特别是JYNNEOS和Lc16m8-已被开发为MPXV感染的预防措施，并且这些疫苗已被证明与前几代相比具有改善的安全性。
